PulmCCM - 25 August 2015
"New oral anticoagulants like dabigatran, apixaban and rivaroxaban have advantages over warfarin: not requiring regular monitoring for efficacy; faster onset of action; shorter half-lives. Unlike warfarin, they've had the significant disadvantage of having no proven antidote for the bleeding that inevitably occurs when any anticoagulant is given to thousands of people. [lawsuits]
Boehringer Ingelheim, makers of the direct thrombin inhibitor dabigatran, announced a solution in a new trial in the New England Journal of Medicine: idarucizumab, a monoclonal antibody that binds dabigatran with 350x the affinity of thrombin."
http://pulmccm.org/main/2015/cardiovascular-disease-review/idarucizumab-works-as-antidote-for-dabigatran-induced-bleeding/